• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Drugs Acting on Glutamate

Drugs Acting on Glutamate

February 1, 2013
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

Subject:
Drugs in the Pipeline

Short Description:
Drugs Acting on Glutamate

Background:
You’re probably hearing a lot of talk about glutamate receptors as a new target for psychiatric therapeutics. As the most abundant excitatory neurotransmitter in the brain, glutamate is thought to play a role in many psychiatric conditions. Some existing drugs act on the glutamate system (eg, lamotrigine and memantine), but more are likely on the way. In fact, several lines of evidence suggest that glutamate function may be disrupted in psychosis and in mood disorders.

Psychosis
Drugs like PCP and ketamine inhibit the NMDA receptor (one of the main glutamate receptor subtypes, others being the AMPA receptor and the metabotropic or “mGluR” receptors). When abused, these drugs can cause a schizophrenia-like syndrome, complete with positive, negative, and cognitive symptoms. Moreover, glutamate synapses also appear to develop abnormally in schizophrenia, and hypofunction of the NMDA receptor has been observed in later stages of the disease (Moghaddam B and Javitt D, Neuropsychopharm 2012;37:4–15). One theory of schizophrenia is that faulty NMDA receptors—present on inhibitory interneurons—are indirectly responsible for the overproduction of glutamate in the prefrontal cortex, where glutamate acts on non-NMDA receptors in a disorganized fashion, possibly contributing to psychosis.Some new antipsychotics under development include drugs that enhance NMDA receptor function and thereby reduce cortical glutamate. Mechanisms of these drugs include the activation of secondary pathways like the metabotropic mGlu5 receptor on NMDA-containing cells (mGlu5 agonists) or the modulation of other metabotropic glutamate receptors found in the cortex (mGlu2/3 agonists). Also, since the NMDA receptor is a complex receptor with binding sites for co-activating molecules like the amino acid glycine, these sites are targets for so-called “allosteric modulators” which, when present, may enhance glutamate signaling at the NMDA receptor.Each of these mechanisms represents a target of current drug development. Results, however, have been mixed. Perhaps the most promising, LY2140023, an mGlu2/3 agonist from Eli Lilly, failed a phase III trial late last year. Roche is developing a glycine transport inhibitor called bitopertin which has shown reductions in negative symptoms in phase II trials. Other trials have focused on sarcosine, a dietary supplement that also works as a glycine transport inhibitor. mGlu5 agonists are still in preclinical (ie, animal) testing. These and other glutamatergic drugs may find a place in the treatment of psychosis in the near future.

Depression
The NMDA receptor has also received a great deal of attention in the treatment of depression, spurred by the observation that subanesthetic doses of intravenous ketamine, an NMDA antagonist, may have a rapid (within hours) and prolonged (up to two weeks) antidepressant effect (Zarate CA et al, Arch Gen Psychiatry2006;63(8):856–864). The mechanism appears to involve the sprouting of neural synapses in the brain and the reversal of stress-induced changes (Li N et al, Science 2010;329(5994):959–964). Some hospitals and clinics have begun to provide this off-label treatment to patients with treatment-resistant depression.Not surprisingly, the excitement surrounding ketamine has led to compounds believed to act similarly. One is GLYX-13, an NMDA partial agonist developed by Naurex, which showed promise in phase IIa trials. This intravenous agent boasts a similar time course of action as ketamine but fewer side effects. Another is AZD6765, an intravenous NMDA antagonist first developed by AstraZeneca as a neuroprotective agent for stroke patients. In treatment responders, sustained benefit isn’t seen until three weeks, calling into question any advantage over current antidepressants. Phase IIb trials for each of these agents are currently under way. Other glutamatergic drugs being studied for depression include an mGlu2/3 antagonist (Roche), an mGluR5 antagonist (Roche), and NMDA antagonists which bind to specific subunits (particularly NR2B) of the NMDA receptor complex.

TCPR’s Take: Currently available treatment options for psychosis and depression leave much to be desired. Lately, attention has been drawn to the glutamate synapse, with several drug companies jockeying to bring new glutamatergic drugs to market. These may represent a significant advance in psychiatric therapeutics, and might be useful adjuncts to existing treatments. Hopefully research will reveal the best use of these agents, specific patients who will benefit, and any possible side effects resulting from their use.
General Psychiatry
KEYWORDS end_of_life_care
    Ccpr octnovdec2020 qa1 headshot spielmans 150x150
    Glen Spielmans, PhD

    L-Methylfolate May Offer Modest Boost to Antidepressants

    More from this author
    www.thecarlatreport.com
    Issue Date: February 1, 2013
    SUBSCRIBE NOW
    Table Of Contents
    A Primer on Palliative Care
    Existential Psychotherapies: An Introduction
    The Role of Psychiatry in Palliative Care
    Is Low Dose Lithium Effective in Bipolar Disorder?
    Drugs Acting on Glutamate
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.